MONTREAL, Nov. 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTCQB:TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS).
Read more at prnewswire.comTetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission
PR Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
